Cytochrome P450c17α 5′-untranslated region *T/C polymorphism in endometriosis

In: Journal of Genetics · 2004 · vol. 83(2) , pp. 189–192 · doi:10.1007/bf02729896 · W2062723728
article OA: closed CC0 ⤵ 14 in-corpus citations
Full text JSON View on OpenAlex View at publisher
AI-generated summary by claude@2026-06+body, 2026-06-08

This study investigated the CYP17 gene's 5'-UTR T/C polymorphism as a potential marker for endometriosis susceptibility and found a trend of increased risk with the T allele, though it may not be a useful predictor.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-09 · read from full text

The paper investigates whether a CYP17 gene polymorphism in the 5′-untranslated promoter region (5′-UTR) involving a T/C variant could serve as a marker for susceptibility to endometriosis, motivated by the role of estrogen biosynthesis in disease pathogenesis. Women were grouped into severe endometriosis (n=119) and non-endometriosis controls (n=128), and the 169-bp fragment around the polymorphic site was genotyped by PCR followed by MspA1I restriction analysis, comparing genotype/allele frequencies between groups. The authors found a higher but non-significant proportion of the T homozygote among endometriosis cases and reported that T allele frequency was associated with higher susceptibility (p=0.046), while overall genotype proportions did not reach statistical significance (p=0.131). The study concludes that CYP17 5′-UTR polymorphism might not be a useful predictive marker for endometriosis susceptibility, and this paper is centrally about endometriosis—specifically assessing the CYP17 5′-UTR T/C polymorphism as a genetic susceptibility marker.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 6,948 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Abstract

Estrogen plays a role in the pathogenesis of endometriosis. The CYP17 gene codes for the cytochrome P450c17α enzyme that is involved in the estrogen biosynthesis. We aimed to investigate if CYP17 polymorphism could be used as marker to predict the susceptibility of endometriosis. Women were divided into two groups: (1) severe endometriosis (n=119); (2) non-endometriosis groups (n=128). A 169-bp fragment encompassing the T/C polymorphic site in 5′-untranslated promoter region (5′-UTR) of the CYP17 was amplified by the polymerase chain reaction, treated with restriction enzyme MspA1I, and electrophoresis. The polymorphism was divided into restriction-enzyme indigestible (T homozygote), T/C heterozygote, and digestible (C homozygote). Genotypes and allelic frequencies for this polymorphism in both groups were compared. We observed a higher but non-significant percentage of T homozygote in the endometriosis women compared with the non-endometriosis women. Proportions of T homozygote/heterozygote/C homozygote for CYP17 in both groups were: (1) 26.1/46.2/27.7% and (2) 17.2/45.3/37.5% (p-value=0.131). T allele was related with higher susceptibility of endometriosis. T and C allele frequencies in both groups were: (1) 49.2/50.8%; (2) 39.8/60.2% (p-value=0.046). Despite the CYP17* T allele appearing to be asscoiatd with a trend of increased risk of endometriosis, CYP17 5′-UTR gene polymorphism might not be a useful marker for prediction of endometriosis susceptibility. Similar content being viewed by others

References

Hadfield R.M. Mardon H.J, Barlow D.H, Kennedy S. 1997 Endometriosis in monozygotic twins.Fertil. Steril. 68, 941–942. Sano M, Inoue S, Hosoi T, Ouchi Y, Emi M, Shiraki M,et al. 1995 Association of estrogen receptor dinucleotide repeat polymorphism with osteeoporosis.Biochem. Biophys. Res. Commun. 217, 378–383. Kennedy S. The genetics of endometriosis. 1998J Reprod. Med. 43, 263–268. Dunning A. M., Healey C. S., Pharoah P. D., Teare M. D., Ponder B. A., Easton D. F. 1999 A systematic review of genetic polymorphisms and breast cancer risk.Cancer. Epidemiol. Biomarkers. Prev. 8, 843–854. Carey A. H., Waterworth D., Patel K., White D., Little J., Novelli P, Franks S, Williamson R. 1994 Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17.Hum. Mol. Genet. 3, 1873–1876. Habuchi T, Liqing Z, Suzuki T, Sasaki R, Tsuchiya N, Tachiki H, Shimoda N, Satoh S, Sato K, Kakehi Y, Kamoto T, Ogawa O, Kato T. 2000 Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect.Cancer Res. 60, 5710–5713. Picado-Leonard J. and Miller W. L. 1987 Cloning and sequence of the human gene for P450c17 (steroid 17 alpha-hydroxylase/ 17,20 lyase): similarity with the gene for P450c21.DNA 6 439–448 Hsieh Y, Chang C, Tsai F, Wu J, Tsai C, Tsai H. 2001a Androgen receptor trinucleotide polymorphism in endometriosis.Fertil Steril. 76 412–413. Chang C.C, Hsieh Y.Y, Wu J.Y, Tsai F.J, Lin C.C, Tsai CH. Yeh LS. Estrogen receptor dinucleotide repeat polymorphism in Taiwan Chinese with endometriosis.J Assist. Reprod. Genet. in press. Chang C. C., Hsieh Y. Y., Tsai F. J., Tsai C. H., Tsai H. D., Lin C. C. 2002 The proline form of p53 codon 72 polymorphism is associated with endometriosis.Fertil. Steril. 77, 43–45. Hsieh Y. Y., Tsai F. J., Chang C. C., Chen W. C., Tsai C. H., Tsai H. D., Lin C. C. 2001b p21 gene codon 31 arginine/serine polymorphism: non-association with endometriosis.J Clin. Lab. Anal. 15, 184–187. Hsieh Y. Y., Chang C. C., Tsai F. J., Hsu Y., Tsai H. D., Tsai C. H. 2002 Polymorphisms for interleukin-4 (IL-4) -590 promoter, IL-4 intron3, and tumor necrosis factor alpha -308 promoter: Non-association with endometriosis.J Clin. Lab. Anal. 16, 121–126. Martucci C. P. and Fishman J. 1993 P450 enzymes of estrogen metabolism.Pharmacol. Ther. 57 23–57 Feigelson H. S., Coetzee G. A., Kolonel L. N., Ross R. K., Henderson B. E. 1997 A polymorphism in the CYP17 gene increases the risk of breast cancer.Cancer Res. 57, 1063–1065. Bergman-Jungestrom M, Gentile M, Lundin A.C, Wingren S. 1999 Association between CYP17 gene polymorphism and risk of breast cancer in young women.Int. J. Cancer 84, 350–353. Young I. E., Kurian K. M., Annink C, Kunkler IH, Anderson VA, Cohen BB, Hooper ML, Wyllie AH, Steel CM. 1999 A polymorphism in the CYP17 gene is associated with male breast cancer.BrJ Cancer 81, 141–143. Feigelson HS, Shames LS, Pike MC, Coetzee GA, Stanczyk FZ, Henderson BE, 1998 Cytochrome P450c17alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations.Cancer Res 58, 585–587. Haiman CA, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Speizer FE, Kelsey KT, Hunter DJ. 1999 The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer.Cancer Res 59, 1015–1020. Diamanti-Kandarakis E, Bartzis MI, Zapanti ED, Spina GG, Filandra FA, Tsianateli TC, Bergiele AT, Kouli CR. 1999 Polymorphism T>C (-34 bp) of gene CYP17 promoter in Greek patients with polycystic ovary syndrome.Fertil Steril 71, 431–435. Haiman CA, Hankinson SE, Colditz GA, Hunter DJ, De Vivo I. 2001 A polymorphism in CYP17 and endometrial cancer risk.Cancer Res 61, 3955–3960. Nedelcheva Kristensen V, Haraldsen EK, Anderson KB, Lonning PE, Erikstein B, Karesen R, Gabrielsen OS, Borresen-Dale AL. 1999 CYP17 and breast cancer risk: the polymorphism in the 5′ flanking area of the gene does not influence binding to Sp-1.Cancer Res 59, 2825–2828. Weston A, Pan CF, Bleiweiss IJ, Ksieski HB, Roy N, Maloney N, Wolff MS. 1998 CYP17 genotype and breast cancer risk.Cancer Epidemiol Biomarkers Prev 7 941–944 Helzlsouer KJ, Huang HY, Strickland PT, Hoffman S, Alberg AJ, Comstock GW, Bell DA. 1998 Association between CYP17 polymorphisms and the development of breast cancer.Cancer Epidemiol Biomarkers Prev 7, 945–949. Techatraisak K, Conway GS, Rumsby G. 1997 Frequency of a polymorphism in the regulatory region of the 17 alpha-hydroxylase-17,20-lyase (CYP17) gene in hyperandrogenic states.Clin Endocrinol (Oxf) 46, 131–134. Dunning AM, Healey CS, Pharoah PD, Foster NA, Lipscombe JM, Redman KL, Easton DF, Day NE, Ponder BA. 1998 No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer.Br J Cancer 77, 2045–2047. Lunn RM, Bell DA, Mohler JL, Taylor JA. 1999 Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).Carcinogenesis 20 1727–1731. Author information Authors and Affiliations Corresponding author Rights and permissions About this article Cite this article Hsieh, YY., Chang, CC., Tsai, FJ. et al. Cytochrome P450c17α 5′-untranslated region *T/C polymorphism in endometriosis. J Genet 83, 189–192 (2004). https://doi.org/10.1007/BF02729896 Received: Revised: Issue date: DOI: https://doi.org/10.1007/BF02729896

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (26)

Cited by (14)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK